Transport of activated nucleotide-sugars into the Golgi is critical for proper glycosylation and mutations in these transporters cause a group of rare genetic disorders termed congenital disorders of glycosylation. We performed exome sequencing on an individual with a profound neurological presentation and identified rare compound heterozygous mutations, p.Thr156Arg and p.Glu196Lys, in the CMPsialic acid transporter, SLC35A1. Patient primary fibroblasts and serum showed a considerable decrease in the amount of N-and O-glycans terminating in sialic acid.
Direct measurement of CMP-sialic acid transport into the Golgi showed a substantial decrease in overall rate of transport. Here we report the identification of the third patient with CMP-sialic acid transporter deficiency, who presented with severe neurological phenotype, but without hematological abnormalities.
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| INTRODUCTION
It is estimated that approximately 1-2% of all human genes encode for proteins involved in various aspects of glycosylation and more than a hundred-glycosylation related genetic disorders have been described (Freeze, Eklund, Ng, & Patterson, 2015; Hennet & Cabalzar, 2015) .
These disorders are collectively termed, congenital disorders of glycosylation (CDG) and categorized by the gene name with a CDG suffix (Freeze, Chong, Bamshad, & Ng, 2014; Jaeken, Hennet, Matthijs, & Freeze, 2009 ).
Mutations affecting the N-linked glycosylation pathway are the most common type with 70 distinct genes identified (Freeze et al., 2014; Scott, Gadomski, Kozicz, & Morava, 2014) . The identification of affected individuals with CDG is often achieved by analyzing the glycosylation status of the abundant serum glycoprotein, transferrin (Tf) (Wada, 2016 ) using a variety of methods including isoelectric focusing (IEF), high performance liquid comatography (HPLC), and electrospray ionization mass spectrometry (ESI-MS) to name a few (Carchon, Chevigné, Falmagne, & Jaeken, 2004; Lacey, Bergen, Magera, Naylor, & O'Brien, 2001; Parente, Ah Mew, Jaeken, & Gilfix, 2010) . We collectively refer to the testing of Tf by any of these or other methods as carbohydrate deficient Tf (CDT) testing.
CDG defects involving the N-linked pathway are divided into two types, type I and type II. CDG-I involves defects in synthesis or transfer a mature lipid linked oligosaccharide (LLO) from its dolichol carrier onto the recipient proteins (Buczkowska, Swiezewska, & Lefeber, 2015; Freeze et al., 2014) . CDG-II involves processing of the protein bound oligosaccharide, which mostly occurs in the Golgi. Dysfunctional Golgiassociated multifunctional protein complexes, alterations in Golgi trafficking, dynamics, homeostasis, pH or ion balance can all lead to CDG-II defects (Freeze et al., 2014) . Another way to directly affect Golgi-dependent glycosylation is by limiting the availability of high energy donor substrates, which are synthesized in the cytoplasm and must be transported into the Golgi to access glycosyltransferases.
Some individuals have pathogenic mutations in these nucleotide-sugar transporters that limit the amount of donor substrate colocated with the glycosyltransferases (Edvardson et al., 2013; Hiraoka et al., 2007; Lübke et al., 2001; Lühn, Wild, Eckhardt, Gerardy-Schahn, & Vestweber, 2001; Martinez-Duncker et al., 2005; Mohamed et al., 2013; Ng et al., 2013) .
Due to the extensive utilization of each nucleotide-sugar by multiple glycosylation pathways, individuals with mutations in these transporters often have biochemical defects involving multiple glycosylation pathways (Xia et al., 2013) Here we report the identification of the third patient with CMPsialic acid transporter deficiency. We present data to expand the molecular, clinical, and biochemical knowledge on SLC35A1-CDG and present a novel cell-based, quantitative assay.
| METHODS AND MATERIALS
| Patient samples
Consent was provided for receiving and using biological sample for family 374 under an approved Sanford Burnham Prebys Medical Discovery institute IRB protocol. Whole blood was drawn from both parents, the affected female and genomic DNA purified using a
Qiagen Puregene blood core kit B (Qiagen, Valencia, CA). Fibroblast cultures were established from a skin biopsy using a standard protocol.
| Exome and sanger sequencing
Exome sequence was performed as previously described (Simon et al., 2017) . Polymerase chain reaction (PCR) using genomic DNA from family-374 was used to amplify exons 4 and 6 of SLC35A1 (NM_006416.4). PCR conditions and primers available upon request.
| SLC35A1 transport assay
Primary fibroblast or Chinese Hamster Ovary (CHO) cells were grown to 80% confluence and permeabilized using hypotonic conditions (Kim, Miura, Etchison, & Freeze, 2001) . Permeablization efficiency was determined by trypan blue staining. CMP-sialic acid transport was carried out as described with the exception that (H 3 ) CMP-sialic acid (American Radiolabeled Chemicals, Inc Saint Louis, MO) was used as the nucleotide-sugar substrate (Kim et al., 2001 ).
| Flow cytometry
Primary fibroblast or CHO cells were grown to 80% confluence and detached using phosphate buffered saline (PBS) supplemented with 5 mM EDTA. Cells were collected and thoroughly washed to remove the residual EDTA then fixed using PBS containing 2% PFA with 2% sucrose for 15 min at room temperature. Cells were again washed with PBS followed by incubation for 1 hr in FACS blocking buffer, 3% IgG free bovine serum albumin (BSA) in PBS. Cells were then incubated for 30 min in blocking buffer with 0.1ug/mL of FITC labeled PNA lectin (EY Labs, Foster City, CA) followed by three washes with blocking buffer to remove unbound lectin.
3 | RESULTS
| Clinical summary
CDG-374 is a twelve-year-old female of German ancestry born to healthy nonconsanguineous parents. She presented early in life with generalized muscular hypotonia and developed seizures at 4 months of age with orofacial tics in clusters of 5-30 seizures (Table 1) . Her seizure type at present involves versive seizures (unnatural, sustained turning of the eyes, or head to one side) to the right.
She initially responded to a combination of valproate and topiramate, and currently is treated with topiramate and lamotrigine. She responded partly and continues to show clusters of three versive seizures to the right every 3-6 months.
Brain magnetic resonance imaging (MRI) showed no gross abnormalities, although there was a small left parietal arachnoidal cyst noted at the age of 11 months. Electroencephalogram (EEG) was normal at onset, but showed slowing over the posterior areas and generalized as well as frontal spikes and polyspikes in the following years.
She has a severe cognitive deficit and the last neurocognitive testing demonstrated an age equivalent to 3-4 years, with an IQ level below 55. She communicates with sounds, or single words (∼50 -100), articulation is difficult to understand due to dysarthria. She has mild ataxic-dyskinetic movements. In addition, she displays autistic features with behavioral problems. Nystagmus is also noted. She has never had coagulation abnormalities nor issues with infections, but has developed thoracolumbar scoliosis (Table 1) . Currently, she receives physical and speech therapies.
All testing for inborn errors in metabolism were normal, until, at 1 year of age she showed a serum Tf type 2 IEF pattern. Follow up analysis of serum TF by ESI-MS confirmed a type 2 pattern with loss of both one and two sialic acids.
| Molecular and biochemical analysis
Exome sequencing of the proband identified two rare compound heterozygous variants, c.467C>G (p.Thr156Arg) and c.586G>A (p.
Glu196Lys), in the CMP-sialic acid transporter SLC35A1 ( We utilized three separate in silico analytical programs to predict potential pathogenicity for each variant. Polyphen2 predicted both variants to be damaging, while SIFT scored the p.Thr156Arg as deleterious and the p.Glu196Lys as tolerated. Our experience is that Combined Annotation Dependent Depletion (CADD) scoring is a better tool for predicting the deleteriousness of a given variant. The CADD score for p.Thr156Arg was 25.8 and for p.Glu196Lys it was 27.7. In comparison, the previously reported pathogenic missense mutation p.Gln101His scored a 27.4. This would place all three variants within the top 0.5% of predicted deleterious mutations in the human genome (Kircher et al., 2014) .
SLC35A1 is predicted to have ten transmembrane domains (TMD)
with the p.Thr156Arg localized to TMD-5 and p.Glu196Lys to TMD-6.
The p.Gln101His reported by Mohamed et al. (2013) occurs within TMD-3. We speculate that these mutations likely disrupt how the transporter is oriented within the membrane. However, it is known that sugar nucleotide transporters can form hetero or homodimers with other transporters and we cannot exclude the possibility that either mutation disrupts these interactions.
We prioritized SLC35A1 as a causal candidate for further biochemical characterization based on CDG-374 having a type 2 pattern showing loss of both one and two sialic acids from serum Tf and the presence of these rare variants.
We used two biochemical approaches to assess the potential defect in CMP-sialic acid transport. The first involved flow cytometry to determine if primary fibroblasts had reduced levels of cell-surfaced glycoproteins terminated with sialic acid (Sia). If an N-or O-glycan lacks a terminal sialic acid, its glycan terminates in a β-galactose (Gal) (Novogrodsky, Lotan, Ravid, & Sharon, 1975) . As a defect in SLC35A1
will affect both N-and O-linked glycans, we choose to use the Oglycan specific peanut lectin (PNA) which recognizes a terminal Gal-β
(1-3)-GalNAc (Lotan & Sharon, 1978) . We determined that CDG-374 had approximately 2.5-fold more PNA reactivity than a control fibroblast line, suggesting less terminal sialic acid on O-linked glycans ( Figure 1 ). As a positive control, we used the established SLC35A1-deficient CHO line, Lec2, to show that SLC35A1 deficiency affects PNA lectin reactivity (Aoki, Ishida, & Kawakita, 2001; Eckhardt, Gotza, & Gerardy-Schahn, 1998 ) (data not shown).
A second biochemical technique is based on the method described by Kim et al. (2001) which uses an artificial glycoside as an acceptor for the transported nucleotide-sugar. In the present case, the glycoside, 4-methylumbelliferone β-galactose (4MU-β-Gal), functions as an acceptor for transported CMP-(H 3 ) sialic acid. The glycoside freely diffuses into the intact Golgi (Etchison & Freeze, 1996; Kim et al., 2001) providing an abundant endogenous acceptor, far in excess of the endogenous glycoprotein acceptors. Under these conditions, the artificial substrate can be sialylated within the Golgi only by the CMP-(H 3 ) sialic acid delivered by transporter. Here permeabilized cells with sealed Golgi (Etchison & Freeze, 1996) are preincubated with 4MU-β-Gal which equilibrates within the Golgi. Addition of CMP-(H 3 ) sialic acid then allows for its transport into the Golgi using SLC35A1. The endogenous sialyltransferase adds sialic acid to the 4MU-β-Gal substrate and the product 4MU-β-Gal(H 3 ) Sia is purified and counted.
Using this method, the patient fibroblast line showed up to a nine-fold lower transport compared to the control. (Figure 2) . Similar results were initially seen when measuring direct transport without using the artificial acceptor (data not shown). CHO-Lec2 was used as a positive control to validate the transport assay (Figure 2 Only one other patient has been reported with proven SLC35A1-CDG. This patient showed macrothrombocytopenia and severe neurological problems including microcephaly, severe developmental disability, hypotonia, and seizures (Mohamed et al., 2013) . She also had dysmorphic features in addition to cardiac abnormalities. As in our patient, this individual had clear sialylation deficiencies in both N-and Olinked glycans on serum glycoproteins, as well as increased levels of Tf missing either one and two sialic acids (Mohamed et al., 2013) (Table 1 ).
The roles of sialic acid in pathogen-host interactions have been well documented both evolutionarily and via animal models (Varki & Schauer, 2009 and Lassa virus utilize sialic acid to highjack cellular machinery (Baggen et al., 2016; Jae et al., 2013) . Knockout cells completely lacking SLC35A1 or other key components of the sialic acid biosynthetic pathway were completely resistant to the effects of either Enterovirus D68 or Lassa virus (Baggen et al., 2016; Jae et al., 2013) .
Perhaps more extensively studied is the role sialylation plays in neurological development, specifically as it relates to polysialic acid (PSA) modification of neural cell adhesion molecule (NCAM). It is well documented that PSA modification of NCAM is critical for neurological development and synaptic plasticity (Hildebrandt, Mühlenhoff, Weinhold, & Gerardy-Schahn, 2007; Hildebrandt & Dityatev, 2015; Schnaar, Gerardy-Schahn, & Hildebandt, 2014) . Thus, loss of SLC35A1
should result in deficient PSA modification of NCAM. Unfortunately, neuronal tissue deficient for SLC35A1 has not been isolated or studied.
CHO mutant cell lines deficient for SLC35A1 have been used to study these effects on PSA, and as expected, global PSA is dramatically altered (Eckhardt et al., 1999; Eckhardt, Mühlenhoff, Bethe, & Gerardy-Schahn, 1996) . This suggests an explanation for the severe neurological phenotype seen in our patient as well as the one reported by Mohamed et al. (2013) .
More recently, CRISPR based screens have shown that SLC35A1
plays an important role in regulating the O-mannosylation of alphadystroglycan (Jae et al., 2013) . This O-mannosylation is critical for alpha-DG function and its disruption causes various forms of muscular dystrophy-dystroglycanopathy (MDDG) syndromes. Interestingly, sialic acid itself seems to be dispensable for alpha-dystroglycan function suggesting that there may be other roles for SLC35A1 (Riemersma et al., 2015) . It is possible that SLC35A1 can transport other nucleotide sugars besides CMP-sialic acid.
In summary, here we describe a patient with compound heterozygous mutations in SLC35A1 and use lectin staining along with a newly developed biochemical assay to confirm the loss of transport activity in patient cells.
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